DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/bhpvvl/investigation) has announced the addition of the "Investigation Report on China's Rituximab Market, 2010-2019" report to their offering. Rituximab (trade name is Rituxan by Roche) was a human- mouse chimeric anti- CD20 monoclonal antibody approved by FDA to treat tumor in 1997. The treatment range of Rituximab extends from B- cell malignant tumors to rheumatoid arthritis, systemic lupus erythematosu
| < Prev | Next > |
|---|
